Can steroids help cancer patients resume a promising therapy?

NCT ID NCT03847649

Recruiting now Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B allows patients from previous studies to continue receiving durvalumab, with or without another drug called tremelimumab. The goal is to see if this approach is safe and can help control cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (with prednisone or tremelimumab)
What this could lead to: If successful, this could offer a way for cancer patients who had severe side effects from immunotherapy to safely resume treatment and potentially control their disease.
What could go wrong: This is a small, early-phase study, so results may not apply broadly. There is a risk that side effects return or that the cancer does not respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

BCCA - Kelowna
RECRUITING

Kelowna, British Columbia, V1Y 5L3, Canada
BCCA - Vancouver
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
RECRUITING

Montreal, Quebec, H2X 3E4, Canada
Cross Cancer Institute
RECRUITING

Edmonton, Alberta, T6G 1Z2, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
Ottawa Hospital Research Institute
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
Regional Health Authority B, Zone 2
RECRUITING

Saint John, New Brunswick, E2L 4L2, Canada
Saskatoon Cancer Centre
RECRUITING

Saskatoon, Saskatchewan, S7N 4H4, Canada
University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Waterloo Regional Health Network (WRHN)
RECRUITING

Kitchener, Ontario, N2G 1G3, Canada
Windsor Regional Cancer Centre
RECRUITING

Windsor, Ontario, N8W 2X3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.